Thus, PBMC transfer with provision of a source of IL-2 in vivo led to the development of a highly sensitive and reproducible xenogenic GVHD model, which would be useful for evaluating immunosuppressive therapeutic regimens, including TRegs therapy. The gene discussed is IL2; the disease is graft versus host disease.